Press release
Neumora Therapeutics, Inc. (NASDAQ: NMRA) Investor Alert: Deadline in Lawsuit on April 7, 2025
A Deadline is coming up on April 7, 2025 in the lawsuit for certain investors in Neumora Therapeutics, Inc. (NASDAQ: NMRA).
Investors who purchased shares of Neumora Therapeutics, Inc. (NASDAQ: NMRA) have certain options and there are strict and short deadlines running. Deadline: April 7, 2025. NASDAQ: NMRA stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
According to the complaint filed in the U.S. District Court for the Southern District of New York the plaintiff alleges on behalf of purchasers of Neumora Therapeutics, Inc. (NASDAQ: NMRA) common shares who purchased NASDAQL NMRA shares in connection with Neumora's IPO, that the defendants violated Federal Securities Laws. More specifically, the plaintiff claims that Offering Documents that were filed in connection with Neumora's September 2023 initial public offering contained false and/or misleading statements and/or failed to disclose that in order for Neumora to justify conducting its Phase Three Program, Neumora was forced to amend BlackThorn's original Phase Two Trial inclusion criteria to include a patient population with moderate to severe MDD to show that Navacaprant offered a statistically significant improvement in treating MDD, that and to that same end, the Company also added a prespecified analysis to the Phase Two statistical analysis plan, focusing on patients suffering from moderate to severe MDD, and that the Phase Two Trials lacked adequate data, particularly in regards to the patient population size and the ratio of male to female patients within the patient population, to be able to accurately predict the results of the KOASTAL-1 study.
Those who purchased shares of Neumora Therapeutics, Inc. (NASDAQ: NMRA) have certain options and should contact the Shareholders Foundation.
Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com
About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Neumora Therapeutics, Inc. (NASDAQ: NMRA) Investor Alert: Deadline in Lawsuit on April 7, 2025 here
News-ID: 3959306 • Views: …
More Releases from Shareholders Foundation
Lawsuit filed for Investors who lost money with shares of Spirit Aviation Holdin …
An investor, who purchased shares of Spirit Aviation Holdings, Inc. (OTC: FLYYQ), filed a lawsuit over alleged violations of Federal Securities Laws by Spirit Aviation Holdings, Inc. in connection with certain allegedly false and misleading statements.
Investors who purchased a significant amount of shares of Spirit Aviation Holdings, Inc. (OTC: FLYYQ) between May 28, 2025 and August 29, 2025, have certain options and for certain investors are short and strict deadlines…
ALERT: Lawsuit filed for Investors who SOLD shares of Sina Corporation (formerly …
An investor, who sold shares of Sina Corporation (formerly NASDAQ: SINA) in the merger between Seina Corporation and TuSimple Holdings, Inc, filed a lawsuit over alleged violations of Federal Securities Laws by Sina Corporation (formerly NASDAQ: SINA in connection with certain allegedly false and misleading statements made.
If you sold a significant amount of shares of Sina Corporation (formerly NASDAQ: SINA) between October 13, 2020 and March 22, 2021, you have…
Lawsuit Alert: Investors who lost money with shares of Fluor Corporation (NYSE: …
An investor, who purchased shares of Fluor Corporation (NYSE: FLR), filed a lawsuit alleged violations of Federal Securities Laws by Fluor Corporation in connection with certain allegedly false and misleading statements.
Investors who purchased shares of Fluor Corporation (NYSE: FLR) have certain options and for certain investors are short and strict deadlines running. Deadline: November 14, 2025. NYSE: FLR investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779…
Investigation announced for Long-Term Investors in shares of Sable Offshore Corp …
An investigation was announced for long-term investors in shares of Sable Offshore Corp. (NYSE: SOC) concerning potential breaches of fiduciary duties by certain directors of Sable Offshore Corp.
Investors who are current long term investors in Sable Offshore Corp. (NYSE: SOC) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term investors in…
More Releases for Neumora
Bipolar Disorder Pipeline Outlook Report 2025: Emerging Therapies, Clinical Deve …
DelveInsight's "Bipolar Disorder Pipeline Insight 2025" report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in the Bipolar Disorder pipeline landscape. It covers the Bipolar Disorder Pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Bipolar Disorder Pipeline Therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Curious about the latest updates…
Biotech's Turning Point: 4 Stocks Poised to Ride the 2025 Wave (MDCX, ACTU, CRBU …
Biotech is entering a new phase of growth in summer 2025, backed by scientific momentum, clinical progress, and a more favorable investment landscape. Following a challenging few years, the sector is rebounding as interest rates ease and investors return to innovative, high-conviction names with late-stage programs and differentiated platforms.
New technologies are accelerating timelines across the board. AI is helping to identify drug targets and biomarkers with greater precision. Machine learning…
Investigation announced for Long-Term Investors in shares of Neumora Therapeutic …
An investigation was announced over potential breaches of fiduciary duties by certain directors and officers of Neumora Therapeutics, Inc.
Investors who are current long term investors in Neumora Therapeutics, Inc. (NASDAQ: NMRA) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term investors in NASDAQ: NMRA stocks follows a lawsuit filed against Neumora Therapeutics,…
Lawsuit filed for Investors in shares of Neumora Therapeutics, Inc. (NASDAQ: NMR …
An investor, who purchased shares of Neumora Therapeutics, Inc. (NASDAQ: NMRA), filed a lawsuitover alleged violations of Federal Securities Laws by Neumora Therapeutics, Inc. in connection with certain allegedly false and misleading statements made in connection with Neumora's September 2023 initial public offering (the "IPO").
Investors who purchased shares of Neumora Therapeutics, Inc. (NASDAQ: NMRA) have certain options and for certain investors are short and strict deadlines running. Deadline: April 7,…
Major Depressive Disorder Clinical Trial Pipeline | 75+ Companies Pioneering the …
Major pharmaceutical companies are working to advance the pipeline space and unlock the future growth potential of the Major Depressive Disorder treatment landscape.
DelveInsight's 'Major Depressive Disorder Pipeline Insight 2024' report provides comprehensive global coverage of pipeline Major Depressive Disorder therapies in various stages of clinical development. Major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Major Depressive Disorder pipeline domain.
For Major Depressive Disorder…
Major depressive disorder Treatment Market 2034: Clinical Trials, Medication, Pi …
Major depressive disorder companies are Takeda Pharmaceuticals, Forest Laboratories, Otsuka Pharmaceuticals, Janssen Research & Development, Axsome Therapeutics, AbbVie, SAGE Therapeutics, Minerva Neurosciences, Luye Pharma, Relmada Therapeutics, BioLite, VistaGen Therapeutics, Praxis Precision Medicines, Intra-Cellular Therapies, Neurocrine Biosciences, Arrivo Bioventures, Chase Therapeutics, Neumora Therapeutics, BlackThorn Therapeutics, Fabre-Kramer Pharmaceuticals, Novartis, more
(Albany, USA) DelveInsight's "Major depressive disorder Market Insights, Epidemiology, and Market Forecast-2034" report delivers an in-depth understanding of Major depressive disorder, historical and…
